-
Physician-Led Peptide and GLP-1 Telehealth Care Now Available Nationwide
Protocol Health has launched Protocol MD, expanding physician-supervised GLP-1 and peptide therapy services, along with online bloodwork access, to patients in all 50 states.
-
Physician-Led Peptide and GLP-1 Care Now Available Nationwide Through New Telehealth Platform
Protocol Health has launched Protocol MD, a physician-led telehealth service offering GLP-1 weight loss treatment, peptide therapy, and at-home bloodwork to patients in all 50 states.
-
HHS Signals Broader Access to Wellness Peptides
The U.S. Department of Health and Human Services has indicated that certain wellness peptides will soon become more widely available, a move that could expand consumer and practitioner access.
-
Easier Access on the Horizon: Peptides May Become More Available in the U.S.
New developments suggest that access to certain peptides in the United States could soon become less restrictive, opening doors for more research and wellness applications.
-
US Policy Shift on Peptide Therapy Sparks Interest in Healing and Longevity Applications Worldwide
A new US regulatory approach to peptide therapy is drawing global attention, including in India, as healthcare observers explore what expanded access could mean for wellness and longevity treatments.
-
HHS Opens Door for Compounding Pharmacies to Prepare Popular Peptides
A new HHS policy will allow specialized pharmacies to compound certain popular peptides for patients, expanding access to therapies that have generated significant patient interest.
-
New Clinical Trial Explores Combining Hepzato Kit with Opdualag for Melanoma Liver Metastases
A new clinical trial is investigating whether pairing the Hepzato Kit with the immunotherapy combination Opdualag can safely improve outcomes for patients with metastatic melanoma that has spread to the liver.
-
New Clinical Trial Explores Promising Combination Therapies for Lung Cancer
A newly registered clinical trial is investigating whether combining tislelizumab with investigational agents can improve outcomes for patients with non-small cell lung cancer, offering a fresh avenue of hope for both high and low PD-L1 expression cases.
-
New Clinical Trial Explores Combination Immunotherapy for Diffuse Large B-cell Lymphoma
A new Phase I/II trial is testing whether combining tafasitamab, retifanlimab, and rituximab with standard chemotherapy can improve outcomes for patients with previously untreated diffuse large B-cell lymphoma.
-
New Clinical Trial Explores Combination Immunotherapy for Diffuse Large B-cell Lymphoma
A new Phase I/II trial is testing whether combining tafasitamab, retifanlimab, and rituximab with standard chemotherapy can improve outcomes for patients with previously untreated diffuse large B-cell lymphoma.